On a roll, Rigel flags a positive PhII for its lead, late-stage drug fostamatinib
Rigel has been having one of those weeks its investors have been dreaming of for years.
First the biotech $RIGL, which has had some mixed news to report on late-stage studies of their drug fostamatinib, helped inspire some confidence on Monday by announcing that the FDA doesn’t need to have a panel review ahead of its PDUFA date.
Score one for the optimists who read that as a tacit acceptance, although there are absolutely no guarantees.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.